Skip to content
Screener

CytomX Therapeutics CTMX Price / book

Price / book at other companies

Pfizer logo
PfizerPFE
1.8×+0.2×
Amgen logo
AmgenAMGN
16.7×-3.4×
Janux Therapeutics logo
Janux TherapeuticsJANX
1×-0.4×
Immunome logo
ImmunomeIMNM
4.6×+1.7×
Arcus Biosciences logo
Arcus BiosciencesRCUS
8.4×+6.7×
CTO
Citius Oncology, Inc.CTOR
1.6×-0.3×

Other financials

Income statement

See full
Revenue$1.4M-92.4%
Operating income-$23.8M-1,749%
Net income-$20.7M-13,319%
EPS (diluted)-$0.09—

Balance sheet

See full
Cash & equivalents$17.2M-64.9%
Total debt$5.7M-17.2%
Total equity$302.1M+152%
Total assets$381.2M+118%

Cash flow

See full
Operating cash flow-$18.1M-14.7%
CapEx--100%
Free cash flow-$18.1M-14.5%

Valuation

See full
Market cap$753.93M+97.9%
Enterprise value$742.41M+119%
P/S41.2×+38.5×

Profitability

See full
Operating margin-476.2%-507pp
Net margin-435.2%-469pp
FCF margin-450.7%-524pp

Returns & leverage

See full
Return on equity-37.8%—
Debt / equity0×0.0×
Current ratio9.4×+5.2×

Where this comes from

Calculated from CytomX Therapeutics’s reported figures.

market cap/total stockholders equity=2.7×

Based on the most recent quarter.

The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-337950

FAQ

What is CytomX Therapeutics's price / book?
CytomX Therapeutics (CTMX) reported price / book of 2.7× in Q2 2026.
How has CytomX Therapeutics's price / book changed year-over-year?
CytomX Therapeutics's price / book decreased by 3.9% year-over-year, from 2.8× to 2.7×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.

Ask your AI about CytomX Therapeutics's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude